FindTrial
Sign In

Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examination

Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examination

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05945524
Acronym
ResisTec
Enrollment
100
Registered
2023-07-14
Start date
2023-09-28
Completion date
2026-05-31
Last updated
2025-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Keywords

Teclistamab, Resistance, Immune Cell

Brief summary

The aim of this study is to discover the immune and oncogenomic features that distinguish patients who respond to teclistamab from patients who are primarily resistant. Moreover, phenotypic and genotypic characteristics that occur with secondary resistance to teclistamab will be analyzed.

Interventions

OTHERBone marrow sampling

Bone marrow sampling collected at 12 weeks after initiation treatment (day 1 cycle 4)

Sponsors

University Hospital, Toulouse
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* With multiple myeloma * Who receive Teclistamab * Consent form signed

Exclusion criteria

* Patient under legal protection

Design outcomes

Primary

MeasureTime frameDescription
Response to teclistamab at 12 weeksat day 1 Cycle 4 (each cycle is 28 days)response according to International Myeloma Working Group criteria

Countries

France

Contacts

Primary ContactHervé AVET LOISEAU, MD, PhD
avetloiseau.herve@iuct-oncopole.fr+33 531 156 142

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026